Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

OBI-3424

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Ascentawits Pharma, OBI Pharma

Drug class:

Alkylating agent

Related drugs:

›

AKR1C3 overexpression	Pancreatic Cancer	AKR1C3 overexpression	Pancreatic Cancer	OBI-3424 Sensitive: C3 – Early Trials OBI-3424 Sensitive : C3	OBI-3424 Sensitive: C3 – Early Trials OBI-3424 Sensitive : C3
AKR1C3 overexpression	Hepatocellular Cancer	AKR1C3 overexpression	Hepatocellular Cancer	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D
BRCA2 mutation + AKR1C3 overexpression	Pancreatic Cancer	BRCA2 mutation + AKR1C3 overexpression	Pancreatic Cancer	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D
BRCA1 mutation + AKR1C3 overexpression	Pancreatic Cancer	BRCA1 mutation + AKR1C3 overexpression	Pancreatic Cancer	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D	OBI-3424 Sensitive: D – Preclinical OBI-3424 Sensitive : D